Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
數字之外：15位分析師討論傳奇生物股票
Across the recent three months, 15 analysts have shared their insights on Legend Biotech (NASDAQ:LEGN), expressing a variety of opinions spanning from bullish to bearish.
在最近的三個月內，15位分析師分享了他們對傳奇生物（NASDAQ: LEGN）的見解，表達了從看好到看淡的各種觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $76.73, a high estimate of $90.00, and a low estimate of $60.00. A decline of 1.15% from the prior average price target is evident in the current average.
分析師評估的12個月價格目標揭示了進一步的見解，包括平均目標爲$76.73，最高估值爲$90.00，最低估值爲$60.00。當前平均目標較之前有1.15%的下降。
Exploring Analyst Ratings: An In-Depth Overview
分析師評級:深入了解
The analysis of recent analyst actions sheds...
分析師近期行動...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。